Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: A population-based case–control study

Authors

  • Michael Hoffmeister,

    1. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany
    Search for more papers by this author
  • Jenny Chang-Claude,

    1. Division of Cancer Epidemiology, Unit of Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany
    Search for more papers by this author
  • Hermann Brenner

    Corresponding author
    1. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany
    • Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Bergheimer Str. 20, D-69115 Heidelberg, Germany
    Search for more papers by this author
    • Fax: +49-6221-548142.


Abstract

Recent research has drawn attention to protective effects of statins on colorectal cancer (CRC) and possible joint effects with other drugs. Because statins are often administered in combination with low-dose aspirin for the prevention of cardiovascular disease, the aim of our study was to investigate individual and combined effects of statins and low-dose aspirin on CRC risk. We assessed use of statins and low-dose aspirin in 540 cases with histologically confirmed incident CRC and 614 control subjects in a population-based case–control study in Germany. Multiple logistic regression was used to estimate the impact of regular use of either low-dose aspirin or statins, and of both drugs combined on CRC risk. We found modest risk reduction of CRC for regular use of low-dose aspirin (adjusted odds ratio 0.77, 95% confidence interval 0.55–1.07) and a stronger association with regular use of statins (OR 0.65, 95% CI 0.43–0.99) or use of both drugs (OR 0.63, 95% CI 0.36–1.10). Combined use of low-dose aspirin and statins was associated with risk reduction by 62% after 5 or more years (OR 0.38, 95% CI 0.15–0.97). Combinational chemoprevention with low-dose aspirin and statins might provide stronger risk reduction than either of the single drugs after at least 5 years use, but confirmation is needed, preferably in prospective cohort studies and eventually by randomized controlled trials. © 2007 Wiley-Liss, Inc.

Ancillary